CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection.

Curr Opin Immunol. 1993 Aug;5(4):484-91. Unique Identifier : AIDSLINE MED/94030690
Riddell SR; Gilbert MJ; Greenberg PD; Fred Hutchinson Cancer Research Center, Seattle.

Abstract: The development of CD8+ cytotoxic T cell responses to viral pathogens is crucial for the prompt resolution of acute infections and for the control of viruses which persist in the host. Thus, cytomegalovirus often causes life threatening disease in immunosuppressed humans who fail to develop or maintain CD8+ cytotoxic T cells. Similarly, the loss of CD8+ cytotoxic T cell responses to HIV correlates with the development of AIDS. Recent investigations in the immunobiology of cytomegalovirus and HIV have resulted in the application of immunotherapeutic strategies designed to reconstitute or augment deficient CD8+ cytotoxic T cell responses to these human pathogens.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/THERAPY Animal Cytomegalovirus Infections/IMMUNOLOGY/*THERAPY Disease Models, Animal Human HIV Infections/IMMUNOLOGY/*THERAPY Immunity *Immunotherapy, Adoptive Mice Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes, Cytotoxic/*IMMUNOLOGY T-Lymphocytes, Suppressor-Effector/*IMMUNOLOGY JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDacquiredimmunodeficiencysyndrome/immunology/therapyanimalcytomegalovirusinfections/immunology/KWDtherapydiseasemodels,animalhumanhivinfections/immunology/KWDtherapyimmunityKWDimmunotherapy,adoptivemicesupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDt-lymphocytes,cytotoxic/KWDimmunologyt-lymphocytes,suppressor-effector/KWDimmunologyjournalarticlereviewreview,tutorial
940228
M9420779

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .